
Last updated: 2026-09-05 19:08:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Indaptus Therapeutics, Inc. (INDP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.21, with a market capitalisation of $155.89M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.92 to $8.57. This page covers its latest market performance, valuation, price trends and company information.
$155.89M | |
$1.18 | |
$807.24 | |
$0.92 | |
$1.16 | |
110.34K | |
-- | |
-- | |
$8.57 | |
$0.92 | |
-- | |
-- |
Indaptus Therapeutics, Inc. (INDP) last closed at $1.16 as of 2026-09-04 23:31:00, unchanged from the previous close of $1.16.
During the latest regular trading session, INDP traded between $0.92 and $807.24, with a volume of 110.34K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Indaptus Therapeutics, Inc. (INDP) moved from $1.14 to $1.21, representing a gain of 5.70% ($0.07).
The stock traded between $1.10 and $1.25 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 205.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.7%
INDP is currently trading at $1.21, placing it 3.7% of the way from its 52-week low of $0.92 to its 52-week high of $8.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Indaptus Therapeutics, Inc. (INDP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.